Muhammet ÇINAR, Emre TEKGÖZ, Sedat YILMAZ, Seda ÇOLAK, Fatma İlknur ÇINAR

Non-adherence to colchicine treatment is a common misevaluation in familial Mediterranean fever

Background/aim: Familial Mediterranean fever (FMF) is a hereditary autoinflammatory disease that requires lifelong colchicine treatment. Colchicine is the mainstay of the treatment, which decreases the frequency and the severity of recurrent FMF attacks and prevents the development of amyloidosis. This study aimed to investigate the rates of colchicine treatment adherence in patients with FMF and the factors related to treatment non-adherence. Materials and methods: This observational study was conducted with 179 patients with FMF between November 2018 and April 2019 in a tertiary rheumatology outpatient clinic. The sociodemographic and clinical data were recorded. Compliance Questionnaire on Rheumatology (CQR) was used to assess the treatment adherence and the Beliefs About Medicines Questionnaire (BMQ-T) was used to assess a patient’s beliefs about colchicine. The factors associated with adherence to the treatment were evaluated. Results: The study included 113 male (63.1%) and 66 (36.9%) female patients with a mean age of 30 (25–44) years. The rate of the patients who declared regular colchicine usage was 66.5%. The frequency of non-adherent patients was 83.8% according to CQR. Treatment adherence was better in patients with comorbid diseases than those without (41.4% vs. 22%, respectively, p = 0.028). The frequency of married patients in the adherent group (72.4%) was higher than the non-adherent group (47.3%) (p = 0.013). The colchicine dose used in the adherent group was 1.5 (1.3–1.8) mg/day, whereas it was 1.5 (1.0–1.5) mg/day in the non-adherent group (p = 0.033). The adherence rate was rising with increasing scores of BMQ-T Specific Necessity. As the scores of BMQ-T General Overuse and General Harm increased, non-adherence to colchicine increased. Conclusion: Evaluating adherence to colchicine treatment with objective methods is crucial to ensure sufficient treatment and prevent amyloidosis. Determining beliefs about colchicine may increase patients’ adherence to treatment.Key words: Adherence, familial Mediterranean fever, colchicine

PDF

___

1. Ozen S, Karaaslan Y, Ozdemir O, Saatci U, Bakkaloglu A et al. Prevalence of juvenile chronic arthritis and familial Mediterranean fever in Turkey: a field study. The Journal of Rheumatology 1998; 25 (12): 2445-2449.
2. Ozdogan H, Ugulu S. Familial Mediterranean Fever. La Presse Medicale 2019; 48: e61-e76. doi: 10.1016/j.lpm.2018.08.014
3. Goldfinger S. Colchicine for familial Mediterranean fever. New England Journal of Medicine 1972; 287 (25): 1302. doi: 10.1056/NEJM197212212872514
4. Colak S, Tekgoz E, Cinar M, Yilmaz S. The assessment of tocilizumab therapy on recurrent attacks of patients with familial Mediterranean fever: A retrospective study of 15 patients. Modern Rheumatology 2020; 31 (1): 223-225. doi: 10.1080/14397595.2019.170925
5. Ben-Chetrit E, Aamar S. About colchicine compliance, resistance and virulence. Clinical and Experimental Rheumatology 2009; 27: S1–S3.
6. Cinar M, Cinar F, Acikel C, Yilmaz S, Çakar M et al. Reliability and validity of the Turkish translation of the beliefs about medicines questionnaire (BMQ-T) in patients with Behçet’s disease. Clinical and Experimental Rheumatology 2016; 34: S46-S51.
7. Breuner C. Alternative and complementary therapies. Adolescent Medical Clinics 2006; 17 (3): 521-546.
8. Horne R, Weinman J, Hankins M. The Beliefs about Medicines Questionnaire: the development and evaluation of a new method for assessing the cognitive representation of medication. Psychology & Health 1999; 14: 1-24. doi: 10.1080/08870449908407311
9. Sohar E, Gafni J, Pras M, Heller H. Familial Mediterranean fever. A survey of 470 cases and review of the literature. The American Journal of Medicine 1967; 43: 227-253.
10. Ozen S, Demirkaya E, Erer B, Livneh A, Ben-Chetrit E et al. EULAR recommendations for the management of familial Mediterranean fever. Annals of the Rheumatic Diseases 2016; 75 (4): 644-651. doi: 10.1136/annrheumdis-2015-208690
11. De Klerk E, Van Der Heijde D, Landewé R, Van Der Tempel H, Van Der Linden S. The Compliance-QuestionnaireRheumatology Compared with Electronic Medication Event Monitoring: a validation study. The Journal of Rheumatology 2003; 30 (11): 2469-2475.
12. Cinar FI, Cinar M, Yilmaz S, Acikel C, Erdem H et al. Crosscultural adaptation, reliability, and validity of the Turkish Version of the Compliance Questionnaire on Rheumatology in patients with Behçet’s disease. Journal of Transcultural Nursing 2016; 27 (5): 480-486. doi: 10.1177/1043659615577699
13. Seyahi E, Ozdogan H, Celik S, Ugurlu S, Yazici H. Treatment options in colchicine resistant familial Mediterranean fever patients: thalidomide and etanercept as adjunctive agents. Clinical and Experimental Rheumatology 2006; 24: S99-S103.
14. Ozen S, Kone-Paut I, Gül A. Colchicine resistance and intolerance in familial mediterranean fever: Definition, causes, and alternative treatments. Seminars in Arthritis and Rheumatism 2017; 47 (1): 115-120. doi: 10.1016/j.semarthrit.2017.03.006
15. Morisky D, Green L, Levine D. Concurrent and predictive validity of a self-reported measure of medication adherence. Medical Care 1986; 24 (1): 67-74. doi: 10.1097/00005650- 198601000-00007
16. Karaaslan Y, Dogan I, Omma A, Sandikci SC. Compliance to colchicine treatment and disease activity in Familial Mediterranean Fever (FMF) patients in Middle/Black Sea Region of Turkey (in Çorum region). Pediatric Rheumatology 2015; 13 (S1): P81.
17. Yesilkaya S, Acikel C, Fidanci BE, Polat A, Sozeri B et al. Development of a medication adherence scale for familial Mediterranean fever (MASIF) in a cohort of Turkish children. Clinical and Experimental Rheumatology 2015; 33: S156-S162.
18. Sönmez HE, Esmeray P, Batu ED, Arıcı ZS, Demir S et al. Is age associated with disease severity and compliance to treatment in children with familial Mediterranean fever? Rheumatology International 2019; 39 (1): 83-87. doi: 10.1007/s00296-018- 4123-0
19. Corsia A, Georgin-lavialle S, Hentgen V, Hachulla E, Grateau G et al. A survey of resistance to colchicine treatment for French patients with familial Mediterranean fever. Orphanet Journal of Rare Diseases 2017; 12: 54. doi: 10.1186/s13023-017- 0609-1
20. Öner A, Erdoǧan Ö, Demircin G, Bülbül M, Memiş L. Efficacy of colchicine therapy in amyloid nephropathy of familial Mediterranean fever. Pediatric Nephrology 2003; 18 (6): 521– 526. doi: 10.1007/s00467-003-1129-x
21. Ozdogan H, Ugurlu S, Hatemi G. Colchicine compliance and amyloidosis. Pediatric Rheumatology 2013; 11 doi: 10.1186/1546-0096-11-S1-A15
22. Yurttas B, Ugurlu S, Ozdogan H. Compliance to colchicine treatment in familial meditterranean fever related amyloidosis. Annals of the Rheumatic Diseases 2017; 76: 415. doi: 10.1136/annrheumdis-2017-eular.5126
23. Katchamart W, Narongroeknawin P, Sukprasert N, Chanapai W, Srisomnuek A. Rate and causes of noncompliance with disease-modifying antirheumatic drug regimens in patients with rheumatoid arthritis. Clinical Rheumatology 2020. doi: 10.1007/s10067-020-05409-5
24. Núñez-Rodríguez J, González-Pérez Y, Nebot-Villacampa M, Zafra-Morales R, Obaldia-Alaña M et al. Adherence to biological therapies in patients with rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis. (Study ADhER-1). Semergen 2020; S1138-3593. doi: 10.1016/j.semerg.2020.06.024
25. Du X, Chen H, Zhuang Y, Zhao Q, Shen B. Medication Adherence in Chinese Patients with Systemic Lupus Erythematosus. Journal of Clinical Rheumatology 2020; 26 (3): 94-98. doi: 10.1097/RHU.0000000000000952
26. Yin R, Cao H, Fu T, Zhang Q, Zhang L et al. The rate of adherence to urate-lowering therapy and associated factors in Chinese gout patients: a cross-sectional study. Rheumatology International 2017; 37 (7): 1187-1194. doi: 10.1007/s00296- 017-3746-x
27. Horne R, Parham R, Driscoll R, Robinson A. Patients’ attitudes to medicines and adherence to maintenance treatment in inflammatory bowel disease. Inflammatory Bowel Diseases 2009; 15 (6): 837-844. doi: 10.1002/ibd.20846
28. Pasma A, Van’t Spijker A, Hazes J, Busschbach J, Luime J. Factors associated with adherence to pharmaceutical treatment for rheumatoid arthritis patients: a systematic review. Seminars in Arthritis and Rheumatism 2013; 43 (1): 18-28. doi: 10.1016/j.semarthrit.2012.12.001
29. Horne R, Chapman S, Parham R, Freemantle N, Forbes A et al. Understanding patients’ adherence-related beliefs about medicines prescribed for long-term conditions: a metaanalytic review of the Necessity-Concerns Framework. PLoS One. 2013; 8 (12): e80633. doi: 10.1371/journal.pone.0080633